[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Views 1,151
Citations 0
April 19, 2016

Incorrect Name in Conflict of Interest Disclosure

JAMA. 2016;315(15):1661. doi:10.1001/jama.2016.3949

In the reply to the Letter to the Editor entitled “Dextromethorphan-Quinidine for Agitation in Alzheimer Disease,” published in the March 15, 2016, issue of JAMA,1 a financial disclosure contained an erroneous name. The second-to-last sentence of the Conflict of Interest Disclosures should have read “Dr Siffert reported being a full-time employee of Avanir Pharmaceuticals and may hold stock or options.” This article was corrected online.

Cummings  JL, Siffert  J.  Dextromethorphan-quinidine for agitation in Alzheimer disease [letter reply]. JAMA. 2016;315(11):1166-1167.PubMedArticle